Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

ROCKVILLE, Md. and SUZHOU, China, Nov. 25, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024.

"I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive directors," said Dr. Dajun Yang, Chairman & CEO of Ascentage Pharma. "Both Ms. Bozilenko and Dr. Yu are accomplished industry veterans possessing a wealth of experience in the finance, investment, business development, and strategic management in the global biopharmaceutical sector. Ascentage Pharma is currently at a crucial stage of its development where we are making further strides with our global innovation strategy. We believe these two distinguished new members of our Board bring with them the invaluable insights and strategic acumen that will help propel the company into its next phase of growth."

Ms. Marina S. Bozilenko is currently the President, CEO and a Director at Biothea Pharma, and an independent director at Talphera, Inc. (NASDAQ: TLPH). Previously, Ms. Bozilenko served as a Managing Director of William Blair & Co. LLC, a Senior Managing Director at Bear, Stearns & Co., Inc., and as a Managing Director at Banc of America Securities LLC. Before that, Ms. Bozilenko held various positions at Vector Securities International, Prudential Vector Healthcare Group, and Kidd & Co. LLC. Additionally, Ms. Bozilenko served as Directors at Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) and SynAct Pharma AB (Nasdaq Stockholm: SYNACT). Ms. Bozilenko received a bachelor's degree in biochemistry and master's degree in social science from the University of Chicago.

Ms. Debra Yu. MD, is currently the Chief Operating Officer and a partner at Panacea Venture, a board member at MeiraGTx Holdings PLC (NASDAQ: MGTX), and an independent non-executive director of JW (Cayman) Therapeutics Co. Ltd (2126. HK). Previously, she served as the Chief Strategy Officer and President at LianBio (NASDAQ: LIAN). Prior to that, she was the Managing Director and head of cross border healthcare investment banking at China Renaissance Securities (U.S.) and the Managing Director of Labrador Advisors, LLC, where she advised numerous cross-border partnerships and licensing transactions. Earlier, she was the Vice President of Strategy at WuXi AppTec; a Senior Director and a leader of the venture capital team and the Worldwide Business Development organization at Pfizer. For many years, Dr. Yu has been a venture capitalist based in the San Francisco Bay Area where she served as a general partner of Delphi Ventures and the Managing Director of Bay City Capital. Dr. Yu has also held positions at McKinsey & Co. and Morgan Stanley. Dr. Yu received a bachelor's degree with high honors in molecular biology from Princeton University and a Doctor of Medicine degree from Harvard Medical School.